Company / EPS (Diluted)
Exelixis EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$0.65
FY2025
5-year range
$0.35 / $1.02
FY2021-FY2025
Trend
+16.1%
vs FY2024
Sector context
#36 of 204
Health Care
What the data says
Exelixis's eps (diluted) of $0.65 is higher than 82% of companies in the Health Care sector (FY2025). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-0.91 in FY2016 to $2.21 in FY2020.
Based on SEC 10-K filings.
0.65 in FY2025 with a 5-year CAGR of -21.7%. Top quartile in the Health Care sector.
Declined from $0.72 to $0.65 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- +22.9%
- 5-Year CAGR
- -21.7%
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 204This company $0.65 Sector average -$0.98
▼
+166.4% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 16.1% year-over-year.
- Ranks #36 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2020.
- Lowest eps (diluted) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.33 (safe zone, above 2.9 threshold)
- Strong profit margin: 29.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 31.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.65 | +16.1% |
| FY2024 | $0.56 | -22.2% |
| FY2023 | $0.72 | +105.7% |
| FY2022 | $0.35 | -65.7% |
| FY2021 | $1.02 | -53.8% |
| FY2020 | $2.21 | +351.0% |
| FY2019 | $0.49 | +275.0% |
| FY2018 | -$0.28 | +63.6% |
| FY2017 | -$0.77 | +15.4% |
| FY2016 | -$0.91 | +31.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026